Blueprint MedicinesBPMC
13F holders, Q1 2026 (March 31)2holders
1new positions
1sold out
$128.18avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Blueprint Medicines Corp. (BPMC) in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Kelleher Financial Advisors ($38K) and Huntington National Bank ($129).
- Company
- Blueprint Medicines Corp.
- CUSIP
- 09627Y109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $38K |
| Exits | 1 | $2.6M |
All 13F filers, Q4 2025 → Q1 2026: 300 shares bought and 25,883 shares sold, net −25,583 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Kelleher Financial Advisors | 0.01% | New | 300 | $38K |
| Huntington National Bank | 0.00% | No change | 1 | $129 |
"% of holder's portfolio" is BPMC's weight in each manager's 13F, not the share of Blueprint Medicines Corp. the manager owns.